CLRB · Cellectar Biosciences, Inc. · Financials
$2.31
-0.06 (-2.53%)
At close · Sep 11
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.83M
Shares
9.45M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$21.79M
+51.1%
FY2025
Diluted EPS
-$8.35
+80.1%
FY2025
Operating Cash Flow
-$23.12M
+51.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13.25M | $11.5M | $26.14M | $27.27M | $18.27M | $17.59M | $10.14M | $9M | $6.84M | $9.47M | $4.75M | $5.16M | $5.96M | $6.86M | $5.12M | $3.6M | $2.98M | — | — | — | — | — | — | — | |
| $10.28M | $11.48M | $25.64M | $11.69M | $10.55M | $6.54M | $5.15M | $5.18M | $4.82M | $4.14M | $4.7M | $3.4M | $3.7M | $4.44M | $3.63M | $2.69M | $1.16M | — | — | — | — | — | — | — | |
| — | $213.6K | $291.65K | $192.38K | $148.44K | $149.92K | $141.45K | $132.8K | $82.27K | $1.55M | $356.67K | $362.5K | $367.2K | $424.76K | $497.25K | $584.84K | $580.11K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $204K | — | $1.1M | — | — | — | — | — | — | — | — | — | — | |
| $23.53M | $22.98M | $51.78M | $38.96M | $28.81M | $24.13M | $15.29M | $14.18M | $13.33M | $13.6M | $9.45M | $8.76M | $9.89M | $12.4M | $8.75M | $7.04M | $4.19M | — | — | — | — | — | — | — | |
| -$23.53M | -$22.98M | -$51.78M | -$38.96M | -$28.81M | -$24.13M | -$15.29M | -$14.18M | -$13.33M | -$13.6M | -$9.45M | -$8.76M | -$9.89M | -$12.4M | -$8.75M | -$7.04M | -$4.19M | — | — | — | — | — | — | — | |
| $1.21M | $1.19M | $7.26M | -$3.87M | -$3.04M | $8918 | $196.18K | $85.71K | $91.74K | $38.68K | $3.27M | $3.26M | $1.84M | $1.62M | -$42.19K | -$397.7K | -$366.58K | — | — | — | — | — | — | — | |
| — | -$21.79M | -$44.52M | -$42.83M | -$31.85M | -$24.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $66K | -$60K | -$60K | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.11M | — | — | — | — | — | — | — | — | |
| -$22.32M | -$21.79M | -$44.58M | -$42.77M | -$31.79M | -$24.12M | -$15.09M | -$14.09M | -$13.24M | -$13.56M | -$6.18M | -$5.5M | -$8.05M | -$10.78M | -$8.8M | -$7.44M | -$4.56M | -$6.22M | -$6.09M | -$5.09M | -$963.44K | -$481.84K | -$342.76K | -$295.79K | |
| — | — | — | — | — | — | — | -$14.09M | -$15.48M | -$15.01M | -$9.36M | — | — | -$10.78M | -$9.34M | -$7.44M | — | — | — | — | — | — | — | — | |
| USD/shares | -$2.56 | -$8.35 | -$36.52 | -$105.00 | -$135.30 | -$130.50 | -$228.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$2.56 | -$8.35 | -$41.89 | -$105.00 | -$135.30 | -$130.50 | -$552.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 2.61M | 1.22M | 407.39K | 235.19K | 185.05K | 66.04K | 25.58K | 9873.24 | 4677.1067 | 14.56K | 2606.5833 | 1530.8867 | 9315.19 | 137.07K | 79.86K | — | — | — | — | — | — | — | — |
| shares | — | 2.61M | 1.24M | 407.39K | 235.19K | 185.05K | 66.04K | 25.58K | 9873.24 | 4677.1067 | 14.56K | 2606.5833 | 1530.8867 | 9315.19 | 137.07K | 79.86K | — | — | — | — | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2013: $0 in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.48×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.10×
Peer medians compare against the 248 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1279704
CUSIP
15117F880
13F (30d)
20 filings
20 filers
Visit website
Investor relations